retatrutide triple agonist glp-1 gip glucagon phase 3 2025 Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports New GLP-3 drug significantly slashes

But theyve also left a lot of people asking the same question: What happens before, during, or after using them?

Discover the evidence linking semaglutide to this digestive side effect, understand why it happens, and learn practical management strategies to reduce symptoms whilst continuing treatment.

Find out in this detailed guide, where we'll compare and contrast the two.

Prescription issued after your doctor consultation, if clinically appropriate

Thirteen trials involving 5,807 participants were identified

Tirzepatide, the first dual GIP/GLP-1 receptor co-agonist approved for type 2 diabetes in the USA, Europe, and the UAE, targets both appetite and glucose control